CN107879961A - A kind of composition for treating liver fibrosis - Google Patents
A kind of composition for treating liver fibrosis Download PDFInfo
- Publication number
- CN107879961A CN107879961A CN201711082592.6A CN201711082592A CN107879961A CN 107879961 A CN107879961 A CN 107879961A CN 201711082592 A CN201711082592 A CN 201711082592A CN 107879961 A CN107879961 A CN 107879961A
- Authority
- CN
- China
- Prior art keywords
- compound
- hepatic fibrosis
- composition
- liver fibrosis
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/10—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Abstract
The invention belongs to field of medicaments, discloses a kind of pharmaceutical composition of anti-hepatic fibrosis, and described pharmaceutical composition includes the compound and pharmaceutically acceptable carrier of effective dose, and the compound has having structure：
Description
Technical field
The present invention relates to pharmaceutical technology field, and in particular to a kind of composition for treating liver fibrosis.
Background technology
Liver fibrosis is commonly called as hepatic sclerosis, refers to caused by various virulence factors connective tissue paraplasm in liver, causes liver
The pathologic process of interior diffusivity extracellular matrix excessive deposition.It is not an independent disease, and many chronic hepatic diseases are equal
Liver fibrosis can be caused.In China, more by drinking, virus hepatitis, bad life habits and induce liver fibrosis, possess every year
Case load is more than 30,000,000 people.It is clinically relatively conventional, because the incidence of disease is high, therefore, being bursting to develop more safely and effectively
The medicine for the treatment of liver fibrosis meets the needs of clinical treatment.
The content of the invention
Goal of the invention：In order to solve the above problems, it is an object of the invention to provide a kind of combination for treating liver fibrosis
Thing.
Technical scheme：The purpose of the present invention is realized by following scheme：
A kind of compound for treating liver fibrosis, the compound have having structure：
One kind treats hepatic fibrosis medicines composition, the compound and pharmaceutically may be used that described pharmaceutical composition includes effective dose
The carrier of receiving, the compound have having structure：
Described treatment hepatic fibrosis medicines composition, the pharmaceutically acceptable carrier are diluent, disintegrant, glued
Mixture, lubricant, stabilizer.
Described treatment hepatic fibrosis medicines composition, the diluent are one kind in lactose or dextrin.
Described treatment hepatic fibrosis medicines composition, described pharmaceutical composition formulation be powder, fine granule, granule,
One kind in capsule or tablet.
Purposes of the compound in treatment hepatic fibrosis medicines are prepared, the compound have having structure：
Studied and found by a large amount of animal experiments, chemical composition of the present invention can notable effect of anti hepatic fibrosis.
Therefore, second object of the present invention is to provide a kind of pharmaceutical applications, i.e., above-mentioned active component is preparing treatment liver fiber
Application in the medicine of change.
Embodiment
Form by the following examples, the above of the present invention is described in further detail again, but should not be by this
The scope for being interpreted as the above-mentioned theme of the present invention is only limitted to following example, and all technologies for being realized based on the above of the present invention are equal
Belong to the scope of the present invention.
Target compound：
Embodiment 1：Target compound of the present invention is studied rat liver fibrosis clinical pharmacology
Experimentation：Rat (Nanjing Medical University's Experimental Animal Center provides) 60 is taken, is randomly divided into Normal group
(distilled water 20ml/kg), carbon tetrachloride model control group (distilled water 20ml/kg), carbon tetrachloride+DDB control group
(0.1g/kg), carbon tetrachloride+target compound of the present invention senior middle school low dose group (10,5,2.5g/kg).Daily gastric infusion one
It is secondary, continuous 45 days, in addition to Normal group, each animal gavage carbon tetrachloride 0.3ml/100g (40% soybean oil solution) every 3 days,
Initial dose 0.5ml/100g.After last dose 24 hours, sacrificed by decapitation animal, take hepatic tissue measure hydroxyproline and liver total
Fat content, it the results are shown in Table 1, table 2.Hepatic tissue pathology section is done simultaneously, the fibrosis of micro- Microscopic observation liver after dyeing, with
Model group is compared.
Influence of the table 1 to hydroxyproline content in rat liver tissue
Influence of the table 2 to total lipid content in rat liver tissue
| Group | Hydroxyproline content (mg/100g) |
| Normal group | 31.76±6.85 |
| Carbon tetrachloride model control group | 42.69±7.43 |
| DDB control group | 26.86±4.80 |
| High dose of the present invention | 25.31±3.76 |
| Middle dosage of the present invention | 27.97±5.43 |
| Low dosage of the present invention | 36.52±9.86 |
Tables 1 and 2 shows, DDB group and high dose group of the present invention can significantly reduce the hydroxyproline in hepatic tissue
Content and total lipid content, middle dose group are taken second place.Check pathological section result shows that DDB group, the present invention are high, middle dose group
Hepatic tissue fibroplasia significantly reduce, have no severe fibrosis occur；The degree of hepatic fibrosis of high dose group of the present invention relatively in
Dosage group is light, and middle dose group relatively low-dose group is light, show dose-effect relation.
Claims (6)
1. a kind of compound for treating liver fibrosis, it is characterised in that the compound has having structure：
2. one kind treats hepatic fibrosis medicines composition, it is characterised in that described pharmaceutical composition includes the compound of effective dose
And pharmaceutically acceptable carrier, the compound have having structure：
3. treatment hepatic fibrosis medicines composition according to claim 2, it is characterised in that described pharmaceutically acceptable
Carrier is diluent, disintegrant, adhesive, lubricant, stabilizer.
4. it is according to claim 3 treatment hepatic fibrosis medicines composition, it is characterised in that the diluent be lactose or
One kind in dextrin.
5. treatment hepatic fibrosis medicines composition according to claim 4, it is characterised in that described pharmaceutical composition formulation
For one kind in powder, fine granule, granule, capsule or tablet.
6. compound is preparing the purposes in treating hepatic fibrosis medicines, it is characterised in that the compound has having structure：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711082592.6A CN107879961A (en) | 2017-11-07 | 2017-11-07 | A kind of composition for treating liver fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711082592.6A CN107879961A (en) | 2017-11-07 | 2017-11-07 | A kind of composition for treating liver fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107879961A true CN107879961A (en) | 2018-04-06 |
Family
ID=61779185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711082592.6A Withdrawn CN107879961A (en) | 2017-11-07 | 2017-11-07 | A kind of composition for treating liver fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107879961A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108689902A (en) * | 2018-09-03 | 2018-10-23 | 范俊 | A kind of additive and the application in the daily chemical products such as shower cream or facial cleanser |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017050990A1 (en) * | 2015-09-25 | 2017-03-30 | Universite De Nantes | 1,4-di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one and the derivatives thereof |
| CN107235883A (en) * | 2016-03-29 | 2017-10-10 | 复旦大学 | Diaryl beta-lactam class compound and preparation method thereof and the purposes in pharmacy |
-
2017
- 2017-11-07 CN CN201711082592.6A patent/CN107879961A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017050990A1 (en) * | 2015-09-25 | 2017-03-30 | Universite De Nantes | 1,4-di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one and the derivatives thereof |
| CN107235883A (en) * | 2016-03-29 | 2017-10-10 | 复旦大学 | Diaryl beta-lactam class compound and preparation method thereof and the purposes in pharmacy |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108689902A (en) * | 2018-09-03 | 2018-10-23 | 范俊 | A kind of additive and the application in the daily chemical products such as shower cream or facial cleanser |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11433114B2 (en) | Composition for cell protection containing cyclo histidine-proline as active ingredient | |
| US10653669B2 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| CA2563058C (en) | Supportive treatment of liver disease | |
| JP2016505050A5 (en) | ||
| US20180353540A1 (en) | Pharmaceutical composition for treating leukemia and preparation method thereof | |
| JP2019531286A5 (en) | ||
| CN107879961A (en) | A kind of composition for treating liver fibrosis | |
| US20090068143A1 (en) | Orally effective cannabinoid analogs | |
| WO2018223625A1 (en) | Pharmaceutical composition and use thereof | |
| IE58734B1 (en) | Use of propiophenone compounds | |
| CN107007614A (en) | The medical usage of cycloastragenol | |
| JP2019535830A5 (en) | ||
| IL300023A (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| CN104721282A (en) | Traditional Chinese composition used for treating hepatic fibrosis | |
| RU2020126396A (en) | USE OF CARRIMYCIN OR ITS ACTIVE INGREDIENTS | |
| US20220304954A1 (en) | Method for the treatment of covid-19 infections with palmitoylethanolamide | |
| US20110124718A1 (en) | Reduction Of Acetaminophen Toxicity By Dietary Milk Thistle Extract | |
| CN105902527A (en) | Medicine composition having blood glucose reduction effect, preparation method and application thereof | |
| CN117243947A (en) | Application of daphnetin and combination containing daphnetin in preparation of diabetes complication medicaments | |
| WO2023034568A1 (en) | Specific therapeutic medical marijuana doses for stress and pain | |
| CN114129554A (en) | Application of 4,4 '-diisothiocyanostilbene-2, 2' -disulfonic acid in preparation of medicine for preventing and treating non-alcoholic fatty liver disease | |
| CN102895244A (en) | Pharmaceutical composition | |
| KR20230159375A (en) | 4-Chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine | |
| CN107648196A (en) | A kind of clarithromycin capsule composition | |
| CN107670019A (en) | A kind of Western medicine compound for treating fatty liver and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180406 |